PIC/S Finds A Way To Solve Divergences With EU ATMP Guide
Executive Summary
A targeted stakeholder consultation will soon be launched on proposals to split the Pharmaceutical Inspection Co-operation Scheme's existing guide on biological products into two parts so as to focus separately on manufacturing issues specific to gene therapy and tissue-engineered products.
You may also be interested in...
PIC/S Proposes Specific GMP Annex For Advanced Therapies
Authorities from the international Pharmaceutical Inspection Co-operation Scheme have suggested splitting the existing Annex 2 of the PIC/S good manufacturing practice guide in a bid to resolve divergences with the EU ATMP manufacturing guide.
New Group To Resolve 'International Divergence' Posed By EU ATMP Guide
Pharmaceutical inspectorates around the world are trying to address the divergences between Europe’s good manufacturing practice guideline on gene therapy and tissue-engineered products and the international GMP guideline for such products.
Commission Defends GMP Guide For ATMPs As PIC/S Cautions Against Divergence
Regulatory authorities participating in the international Pharmaceutical Inspection Co-operation Scheme are concerned that the European Commission’s proposed good manufacturing practice guideline on advanced therapy medicinal products diverges from PIC/S requirements and will result in lower regulatory standards. The commission defends its approach, saying the guideline will result in high-quality ATMPs and ensure patient protection.